Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
Background/Aims The short- and long-term effects of adalimumab (ADA) on Korean patients with intestinal Behcet’s disease (BD) for remain unclear. Therefore, a multicenter study was performed to evaluate the efficacy and safety of ADA in Korean patients with intestinal BD in a real-world setting. Met...
| Principais autores: | , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
The Korean Association of Internal Medicine
2023-09-01
|
| coleção: | The Korean Journal of Internal Medicine |
| Assuntos: | |
| Acesso em linha: | http://kjim.org/upload/kjim-2022-394.pdf |
| _version_ | 1827822231079616512 |
|---|---|
| author | Seung Bum Lee Hee Seung Hong Chang Kyun Lee Bo-In Lee Sol Kim Seong-Joon Koh Hosun Yu Jung-Bin Park Sung Wook Hwang Byong Duk Ye Suk-Kyun Yang Sang Hyoung Park |
| author_facet | Seung Bum Lee Hee Seung Hong Chang Kyun Lee Bo-In Lee Sol Kim Seong-Joon Koh Hosun Yu Jung-Bin Park Sung Wook Hwang Byong Duk Ye Suk-Kyun Yang Sang Hyoung Park |
| author_sort | Seung Bum Lee |
| collection | DOAJ |
| description | Background/Aims The short- and long-term effects of adalimumab (ADA) on Korean patients with intestinal Behcet’s disease (BD) for remain unclear. Therefore, a multicenter study was performed to evaluate the efficacy and safety of ADA in Korean patients with intestinal BD in a real-world setting. Methods The medical records of 67 patients with BD prescribed ADA between January 2012 and December 2020 at five referral centers in Korea were retrospectively analyzed and the safety and efficacy of ADA within 52 weeks were assessed. To evaluate the clinical efficacy of ADA, the Disease Activity Index for Intestinal BD (DAIBD) and representative blood biochemical markers were compared at 0, 12, 24, and 52 weeks of ADA treatment. Results During the follow-up period of 52 weeks, 46 patients continued ADA treatment. The cumulative drug survival rate was 83.5%. The DAIBD score decreased over the study period (p < 0.001). Moreover, the erythrocyte sedimentation rate, serum C-reactive protein levels, and serum albumin levels significantly improved at 12, 24, and 52 weeks of ADA treatment (all, p <0.05). Conclusions As ADA is effective for refractory intestinal BD with few safety concerns in real-world situations, it is a potential treatment option for Korean patients with intestinal BD. |
| first_indexed | 2024-03-12T01:54:08Z |
| format | Article |
| id | doaj.art-5366d33b6922447e95aa9c179de4df06 |
| institution | Directory Open Access Journal |
| issn | 1226-3303 2005-6648 |
| language | English |
| last_indexed | 2024-03-12T01:54:08Z |
| publishDate | 2023-09-01 |
| publisher | The Korean Association of Internal Medicine |
| record_format | Article |
| series | The Korean Journal of Internal Medicine |
| spelling | doaj.art-5366d33b6922447e95aa9c179de4df062023-09-08T06:41:56ZengThe Korean Association of Internal MedicineThe Korean Journal of Internal Medicine1226-33032005-66482023-09-0138566167110.3904/kjim.2022.394170823Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter studySeung Bum Lee0Hee Seung Hong1Chang Kyun Lee2Bo-In Lee3Sol Kim4Seong-Joon Koh5Hosun Yu6Jung-Bin Park7Sung Wook Hwang8Byong Duk Ye9Suk-Kyun Yang10Sang Hyoung Park11 Department of Gastroenterology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Center for Crohn’s and Colitis, Department of Gastroenterology, Kyung Hee University College of Medicine, Seoul, Korea Division of Gastroenterology, Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Korea Division of Gastroenterology, Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Korea Division of Gastroenterology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea Division of Gastroenterology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaBackground/Aims The short- and long-term effects of adalimumab (ADA) on Korean patients with intestinal Behcet’s disease (BD) for remain unclear. Therefore, a multicenter study was performed to evaluate the efficacy and safety of ADA in Korean patients with intestinal BD in a real-world setting. Methods The medical records of 67 patients with BD prescribed ADA between January 2012 and December 2020 at five referral centers in Korea were retrospectively analyzed and the safety and efficacy of ADA within 52 weeks were assessed. To evaluate the clinical efficacy of ADA, the Disease Activity Index for Intestinal BD (DAIBD) and representative blood biochemical markers were compared at 0, 12, 24, and 52 weeks of ADA treatment. Results During the follow-up period of 52 weeks, 46 patients continued ADA treatment. The cumulative drug survival rate was 83.5%. The DAIBD score decreased over the study period (p < 0.001). Moreover, the erythrocyte sedimentation rate, serum C-reactive protein levels, and serum albumin levels significantly improved at 12, 24, and 52 weeks of ADA treatment (all, p <0.05). Conclusions As ADA is effective for refractory intestinal BD with few safety concerns in real-world situations, it is a potential treatment option for Korean patients with intestinal BD.http://kjim.org/upload/kjim-2022-394.pdfadalimumabbehcet syndrometreatment outcome |
| spellingShingle | Seung Bum Lee Hee Seung Hong Chang Kyun Lee Bo-In Lee Sol Kim Seong-Joon Koh Hosun Yu Jung-Bin Park Sung Wook Hwang Byong Duk Ye Suk-Kyun Yang Sang Hyoung Park Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study The Korean Journal of Internal Medicine adalimumab behcet syndrome treatment outcome |
| title | Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study |
| title_full | Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study |
| title_fullStr | Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study |
| title_full_unstemmed | Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study |
| title_short | Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study |
| title_sort | real world effectiveness and safety of adalimumab in korean patients with intestinal behcet s disease a korean association for the study of intestinal diseases kasid multicenter study |
| topic | adalimumab behcet syndrome treatment outcome |
| url | http://kjim.org/upload/kjim-2022-394.pdf |
| work_keys_str_mv | AT seungbumlee realworldeffectivenessandsafetyofadalimumabinkoreanpatientswithintestinalbehcetsdiseaseakoreanassociationforthestudyofintestinaldiseaseskasidmulticenterstudy AT heeseunghong realworldeffectivenessandsafetyofadalimumabinkoreanpatientswithintestinalbehcetsdiseaseakoreanassociationforthestudyofintestinaldiseaseskasidmulticenterstudy AT changkyunlee realworldeffectivenessandsafetyofadalimumabinkoreanpatientswithintestinalbehcetsdiseaseakoreanassociationforthestudyofintestinaldiseaseskasidmulticenterstudy AT boinlee realworldeffectivenessandsafetyofadalimumabinkoreanpatientswithintestinalbehcetsdiseaseakoreanassociationforthestudyofintestinaldiseaseskasidmulticenterstudy AT solkim realworldeffectivenessandsafetyofadalimumabinkoreanpatientswithintestinalbehcetsdiseaseakoreanassociationforthestudyofintestinaldiseaseskasidmulticenterstudy AT seongjoonkoh realworldeffectivenessandsafetyofadalimumabinkoreanpatientswithintestinalbehcetsdiseaseakoreanassociationforthestudyofintestinaldiseaseskasidmulticenterstudy AT hosunyu realworldeffectivenessandsafetyofadalimumabinkoreanpatientswithintestinalbehcetsdiseaseakoreanassociationforthestudyofintestinaldiseaseskasidmulticenterstudy AT jungbinpark realworldeffectivenessandsafetyofadalimumabinkoreanpatientswithintestinalbehcetsdiseaseakoreanassociationforthestudyofintestinaldiseaseskasidmulticenterstudy AT sungwookhwang realworldeffectivenessandsafetyofadalimumabinkoreanpatientswithintestinalbehcetsdiseaseakoreanassociationforthestudyofintestinaldiseaseskasidmulticenterstudy AT byongdukye realworldeffectivenessandsafetyofadalimumabinkoreanpatientswithintestinalbehcetsdiseaseakoreanassociationforthestudyofintestinaldiseaseskasidmulticenterstudy AT sukkyunyang realworldeffectivenessandsafetyofadalimumabinkoreanpatientswithintestinalbehcetsdiseaseakoreanassociationforthestudyofintestinaldiseaseskasidmulticenterstudy AT sanghyoungpark realworldeffectivenessandsafetyofadalimumabinkoreanpatientswithintestinalbehcetsdiseaseakoreanassociationforthestudyofintestinaldiseaseskasidmulticenterstudy |